Brain

Fortifeye Vitamins Breaks New Ground With Next Gen Zinc-Free Macular Degeneration Formula

Fortifeye Vitamins Introduces Next Gen Zinc-Free Macular DefenseOCALA, FL / ACCESSWIRE / July 25, 2023 / Fortifeye Vitamins, a leading…

1 year ago

SamanTree Medical Appoints New Chief Executive Officer

Histolog® Scanner has been used in 2000 procedures, adoption is acceleratingLAUSANNE, Switzerland--(BUSINESS WIRE)--#medicalimaging--SamanTree Medical, a medical technology company specializing in…

1 year ago

Hyperfine, Inc. to Announce Second Quarter Financial Results on August 14, 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared…

1 year ago

MDbio – The Doctors BrandTM Publishes New Article About Artificial Intelligence in Healthcare

Beverly Hills, California, July 24, 2023 (GLOBE NEWSWIRE) --  MDbio – The Doctors BrandTM published a new article about artificial intelligence…

1 year ago

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing…

1 year ago

The Garry Hurvitz Centre for Community Mental Health at SickKids Selects VitalHub to implement its TREAT Client Information System to Enhance Client Care

TORONTO, July 24, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is excited to announce a…

1 year ago

Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX),…

1 year ago

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for…

1 year ago

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ETBRISBANE, Calif.,…

1 year ago